| Similar Articles |
|---|
 |
The Motley Fool
November 4, 2011
Anders Bylund |
Optimer Pharmaceuticals Shares Dropped: What You Need to Know Shares of Optimer Pharmaceuticals, which develops advanced hospital products such as highly specialized antibiotics, fell as much as 15.7% today on very heavy trading.   |
The Motley Fool
May 31, 2011
Brian Orelli |
Down! Up! Which Way Will Optimer Go Next? Long-term prospects look good. |
The Motley Fool
April 6, 2011
Brian Orelli |
Killing Bacteria With the Help of a Friend Optimer Pharmaceuticals has signed up Cubist Pharmaceuticals as a marketing partner for at least the next two years. |
The Motley Fool
August 5, 2011
Brian Orelli |
Still Want to Be the Next Dendreon? The biotech market is punished. |
The Motley Fool
April 30, 2010
Brian Orelli |
Pricey Provenge Pumps Up Dendreon Dendreon's prostate cancer drug is approved, but at what cost, and will insurance pay for it? |
The Motley Fool
November 3, 2011
Brian Orelli |
Modest Growth, Less-Than-Modest Stock Drop Dendreon's investors aren't happy. |
The Motley Fool
August 10, 2011
Jim Mueller |
Rising Star Buy: Digging Dendreon After getting hammered, there's an opportunity here. |
The Motley Fool
May 25, 2011
Brian Orelli |
Optimer's Upcoming FDA Decision: Memorable or Memorial? We'll know on Memorial Day, plus or minus a few days. |
The Motley Fool
June 5, 2007
Brian Lawler |
Dendreon Gets Its Funding Dendreon does a financing to secure its near-term future. Investors who fail to pay attention to relative valuations of the different stocks in the development-stage biotech space do so at their own peril. |
The Motley Fool
June 19, 2009
Brian Orelli |
Dendreon Is No Dot-Com Story ... Yet Is Dendreon a bad buy at today's prices? Not if it gets cancer treatment Provenge approved. And there's the risk. |
The Motley Fool
September 29, 2010
Brian Orelli |
Better Buy: Spectrum Pharmaceuticals or Dendreon? A battle of the sales-ramping drugmakers. |
The Motley Fool
September 22, 2010
Brian Orelli |
A Dendreon Deal: It's Not What You Think Dendreon gets help manufacturing Provenge, but there's still work ahead. |
The Motley Fool
March 13, 2008
Brian Lawler |
Dendreon Rolls the Dice The pharmaceutical amends a phase 3 study on its lead prostate cancer drug. |
The Motley Fool
June 1, 2007
Brian Lawler |
Dendreon Gains. Why? Shares of the biopharma rise after it announces already expected news. |
The Motley Fool
August 29, 2011
Brian Orelli |
We Can Make More! Too Bad Few Want It Dendreon is no longer constrained by its supply. |
The Motley Fool
May 10, 2006
Brian Lawler |
Dendreon Drives On Will the FDA say yes to a new cancer drug? Investors, take note. |
The Motley Fool
April 14, 2009
Brian Orelli |
Sell Dendreon! No, Buy Dendreon! Dendreon, everyone's favorite tiny biotech, just got bigger because of positive phase 3 results for its prostate cancer treatment, Provenge. |
The Motley Fool
January 17, 2007
Brian Lawler |
Dendreon in the Fast Lane The FDA speeds up review of Dendreon's leading drug candidate. Investors, take note. |
The Motley Fool
December 14, 2007
Brian Lawler |
Ignore the Dendreon Hoopla A Congressional probe request will have no effect on Dendreon or Provenge's odds at making it through the FDA, since it was not the FDA reviewers of the Provenge marketing application that were accused of anything bad. |
The Motley Fool
November 23, 2011
Brian Orelli |
I Was Wrong About Dendreon But maybe not in the long term. |
The Motley Fool
August 31, 2010
Brian Orelli |
What Is Dendreon Worth? Now that's a good question, isn't it? |
The Motley Fool
September 25, 2009
Brian Orelli |
Dendreon Struts Its Stuff Like a peacock without any FDA-approved feathers. |
The Motley Fool
April 29, 2009
Brian Orelli |
2 Lessons From Dendreon Traders beware. |
The Motley Fool
December 16, 2011
Brian Orelli |
Dendreon 2011: Supply Constrained to Missed Guidance A year in review for the biotech. |
The Motley Fool
August 4, 2010
Brian Orelli |
Dendreon Doubles Up The biotech enjoys twice as much revenue month over month. |
The Motley Fool
November 2, 2011
David Williamson |
After Hours: Dendreon's Shares Crushed Again Bad guidance in third quarter earnings punishes this stock. |
The Motley Fool
March 2, 2011
Brian Orelli |
When Will Dendreon Make Money? Not for awhile ... it's a biotech thing. |
The Motley Fool
January 5, 2012
David Williamson |
Dendreon Investors: Why Shares Are Soaring Tripling Provenge sales causes shares to soar 50%. |
The Motley Fool
February 15, 2008
Brian Lawler |
Dendreon's Not-So-New Data Development-stage drugmaker Dendreon releases "new data" on lead cancer drug Provenge; unfortunately, the data wasn't the data that investors are waiting for. |
BusinessWeek
October 6, 2003
Gene G. Marcial |
Dendreon: New Weapons against Tumors What's so hot about Dendreon, which leaped from 3 last year to 9.25 on Sept. 24? The little-known biotech develops immunologically based cancer remedies, and its lead product, Provenge, is aimed at prostate cancer. |
The Motley Fool
August 8, 2011
Luke Timmerman |
Dendreon Wounds Are Self-Inflicted, Not the Start of a Biotech Industry Virus Is Dendreon doomed? |
The Motley Fool
June 30, 2011
Brian Orelli |
Dendreon Increases Potential Output, More to Come Los Angeles plant is approved. |
The Motley Fool
September 28, 2010
Brian Orelli |
It's Up! It's Down! It's Dendreon! The joys of biotech. |
The Motley Fool
August 18, 2010
Travers & Greer |
Dendreon's Big Pharma Future Dendreon has had success with its prostate cancer treatment Provenge. What does Provenge's success mean for the future of Dendreon? |
The Motley Fool
January 20, 2004
Dave Marino-Nachison |
Dendreon Calls for Cash Investors don't mind a secondary offering when it comes on the coattails of good news. |
The Motley Fool
May 3, 2011
Brian Orelli |
Brakes Are Off at Dendreon Ramping up sales, one month at a time. |
The Motley Fool
September 30, 2011
David Williamson |
This Week in Biotech Biotech news about Array BioPharma, Human Genome Sciences, Pharmasset, and more. |
The Motley Fool
November 18, 2010
Brian Orelli |
Worry-Free Dendreon? One step closer to national reimbursement from the Centers for Medicare and Medicaid Services to pay for its prostate cancer treatment Provenge. |
The Motley Fool
July 1, 2011
Luke Timmerman |
Dendreon Sways Medicare to Pay for Prostate Cancer Drug The decision by Medicare is no surprise, but it does conclude a period of uncertainty about insurance reimbursement for its lone marketed product. |
The Motley Fool
April 4, 2011
Brian Orelli |
Anti-Infective, Very Effective The FDA seems to like Optimer's new antibiotic. |
The Motley Fool
April 1, 2011
Travis Hoium |
Optimer Pharmaceuticals Shares Popped: What You Need to Know Shares of Optimer Pharmaceuticals jumped 12% today after positive news from the FDA was released. |
The Motley Fool
January 12, 2004
Dave Marino-Nachison |
All Eyes on Dendreon The cancer fighter's shares rocketed today on good news out of Phase III trials. |
The Motley Fool
November 16, 2007
Brian Lawler |
Waiting on a Friend for Dendreon Dendreon looks for a marketing partner for a prostate cancer drug that's in clinical trials. Investors, take note. |
The Motley Fool
September 1, 2010
Brian Orelli |
Dendreon: One Step Closer to Worry-Free Back in July, the Centers for Medicare & Medicaid Services announced that it planned on reviewing the reimbursement for Dendreon's prostate cancer treatment Provenge. |
The Motley Fool
June 1, 2010
Brian Orelli |
Save Your Money, Dendreon As much as doctors would like to prescribe Dendreon's Provenge for their patients, manufacturing limitations will keep demand outpacing supply for awhile. |
The Motley Fool
May 4, 2009
Robert Steyer |
Beyond Provenge -- The Next Hot Cancer Drug? The search for prostate cancer treatments is filled with prospects and littered with failures. Which companies have the best chance of success? |
The Motley Fool
August 11, 2011
Brian Orelli |
Dendreon's a Broken IPO, Again $10 isn't really a magical number. |
The Motley Fool
October 31, 2008
Brian Orelli |
World's Scariest Stock: Dendreon The fear of the unknown makes investing scary, and things don't get much more unknown than the future of biotech company Dendreon. |
The Motley Fool
July 1, 2011
Brian Orelli |
Dendreon Is Drama-Free ... for Now For a drug that has had so much drama during its existence, the final decision by the Centers for Medicare and Medicaid Services to pay for Dendreon's prostate cancer treatment Provenge was pretty anticlimactic. |
The Motley Fool
January 7, 2011
Brian Orelli |
Dendreon Heads Across the Pond A pathway to Provenge approval in the EU. |
